QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial

Unicorn Hunters S1 EP4: Intrommune

Written by Entrepreneur
June 21, 2021

More than half a billion people live with food-related allergies around the world, and Intrommune Therapeutics aims to help them live without fear by transforming allergy immunotherapy with its revolutionary treatment platform, a toothpaste that delivers proteins to the immune system allowing food allergy sufferers to develop a gradual immunity. 

Intrommune’s immunotherapy toothpaste, known as INT301 is in Phase 1 clinical development for patients with peanut-related allergies and a second toothpaste product designed to address other food allergies is in development. With an estimated $7 Billion per year market potential in the US, and an even greater potential across the globe, Intrommune Therapeutics is poised for growth, aided by its global, exclusive rights to 35 patents. To learn more about Intrommune, watch the newest episode streaming on Unicorn Hunters now.

Watch Unicorn Hunters on demand and if you are intestered in investing, click here.

Should you invest $1,000 in S1 right now?

Before you consider S1, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and S1 wasn't on the list.

While S1 currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
More From MarketBeat
[Urgent!] Generational Wealth Gameplan
from Crypto 101 Media
13 Stocks With Strong Institutional Buying
from MarketBeat
Biden’s $374B Giveaway Into This Sector
from DTI
20 Stocks Wall Street Analysts Love the Most
from MarketBeat
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
from Paradigm Press
The Top-Rated Dividend Stocks for 2023
from MarketBeat
The Next Nvidia?
from InvestorPlace
The Best Energy Stocks to Buy Now
from MarketBeat

Featured Articles and Offers

Recent Videos

Johnson & Johnson’s Dip is a Strategic Buy Point for Investors
Johnson & Johnson's Dip is a Strategic Buy Point for Investors
7 Cheap Dividend Stocks Offering Value and Price Upside
7 Cheap Dividend Stocks Offering Value and Price Upside
Early Stage-Investing: Spot Top Startups and Secure the Best Valuations
Early Stage-Investing: Spot Top Startups and Secure the Best Valuations
Delta Air Lines Stock Should Take Flight After Solid Report
Delta Air Lines Stock Should Take Flight After Solid Report
Search Headlines: